Recovery Act Limited Competition: Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3)
The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
06/02/2009
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Description of Modification
This is to notify potential applicants of Important Registration Reminders for Businesses Submitting in Response to New Recovery Act Funding Opportunity Announcements. See Notice NOT-OD-09-126 for details at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-126.html.
Document Type:
Modification to Previous
Grants Notice
Funding Opportunity Number:
RFA-OD-09-008
Opportunity Category:
Other
Posted Date:
Jun 02, 2009
Creation Date:
Jul 24, 2009
Original Closing Date for Applications:
Sep 01, 2009
Current Closing Date for Applications:
Sep 01, 2009
Archive Date:
Oct 02, 2009
Funding Instrument Type:
Grant
Category of Funding Activity:
Health
Recovery Act
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
Award Ceiling:
$1,000,000
Award Floor:
CFDA Number(s):
93.701
--
Trans-NIH Recovery Act Research Support
Cost Sharing or Matching Requirement:
No
Eligible Applicants
For profit organizations other than small businesses
Small businesses
Additional Information on Eligibility:
Other Eligible Applicants include the following:
This FOA encourages submissions by United-States for-profit enterprises/commercial organizations doing a majority of their business in the United States. Applications received under this FOA may be given funding priority if the applicant is associated with an enterprise/commercial organization that is of small size (e.g., 500 or fewer employees), and/or of limited resources, such as an early-stage company, and/or one positioned for receiving funding or in-kind support from a third-party investor and/or strategic partner.
The applicant United States institution/organization must be located in the 50 states, territories and possessions of the U.S., Commonwealth of Puerto Rico, Trust Territory of the Pacific Islands, or District of Columbia. NIH encourages applications from all interested organizations/institutions, including those from Institutional Development Award (IDeA) states. Foreign organizations/institutions are not permitted as the applicant organization.
If the application includes subcontractors, the applicant for-profit enterprise/commercial organization must be substantially involved in the R and D, with a leadership role in the project and defining the research agenda.
Agency Name
National Institutes of Health
Description
Purpose. This Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits grant applications for a new initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3). The purpose of this pilot program is to address the funding gap between promising research and development (R and D) and transitioning to the market -- often called the Valley of Death -- by contributing to the critical funding needed by applicants to pursue the next appropriate milestone(s) toward ultimate commercialization; i.e., to carry out later stage research activities necessary to that end. This program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of research and development (R and D) collaborators working toward these aims. Mechanism of Support. This FOA will utilize the RC3 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $35 million in response to this FOA. We anticipate that at least 10 awards will be made in fiscal year 2010, pending the number and quality of applications and availability of funds. As a pilot, an evaluation will be necessary before any reissuance of this FOA; any reissuance is also predicated on funds availability. Applications received under this FOA may be given funding priority if the project is deemed to have high commercial potential to be developed into a product or service as indicated by the underserved need being addressed, the lack of alternative resources in the market and/or the applicants ability to secure funding or in-kind support from an independent third-party investor and/or strategic partner.
The following files represent the modifications to this synopsis
with the changes noted within the documents. The list of files is
arranged from newest to oldest with the newest file representing the
current synopsis. Changed sections from the previous document are shown
in a light grey background.
